Householder Group Estate & Retirement Specialist LLC Grows Stock Position in Merck & Co., Inc. (NYSE:MRK)

Householder Group Estate & Retirement Specialist LLC boosted its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,248 shares of the company’s stock after buying an additional 220 shares during the period. Householder Group Estate & Retirement Specialist LLC’s holdings in Merck & Co., Inc. were worth $899,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Cantor Fitzgerald Investment Advisor L.P lifted its position in Merck & Co., Inc. by 94.2% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 349,588 shares of the company’s stock valued at $28,683,000 after purchasing an additional 169,536 shares during the period. BCK Partners Inc. acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at approximately $2,423,000. NewEdge Advisors LLC boosted its stake in shares of Merck & Co., Inc. by 6.3% in the first quarter. NewEdge Advisors LLC now owns 159,225 shares of the company’s stock valued at $13,064,000 after buying an additional 9,376 shares in the last quarter. First Western Trust Bank acquired a new position in Merck & Co., Inc. during the first quarter worth $1,078,000. Finally, Equitable Holdings Inc. raised its position in Merck & Co., Inc. by 12.9% in the first quarter. Equitable Holdings Inc. now owns 36,124 shares of the company’s stock worth $2,964,000 after acquiring an additional 4,131 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the completion of the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now directly owns 19,569 shares in the company, valued at $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Stock Down 0.3 %

MRK opened at $130.01 on Wednesday. The firm has a market cap of $329.27 billion, a P/E ratio of 931.07, a PEG ratio of 0.52 and a beta of 0.38. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. The business’s fifty day simple moving average is $125.45 and its 200 day simple moving average is $113.20. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The company had revenue of $14.63 billion for the quarter, compared to the consensus estimate of $14.49 billion. During the same quarter last year, the firm posted $1.62 earnings per share. Merck & Co., Inc.’s revenue was up 5.8% on a year-over-year basis. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 2.37%. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MRK shares. Wells Fargo & Company upped their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. TD Cowen upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target for the company. in a research report on Monday, March 11th. Barclays boosted their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $129.71.

Read Our Latest Analysis on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.